Trial Profile
Efficacy of epinastine hydrochloride ophthalmic solution after switched from olopatadine hydrochloride ophthalmic solution in elderly patients with perennial allergic conjunctivitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Epinastine (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 03 Jun 2016 Status changed from recruiting to completed.
- 09 Dec 2015 Planned End Date changed from 31 Mar 2015 to 31 Dec 2015 as reported by University hospital Medical Information Network-Japan record.
- 04 Dec 2014 New trial record